Stocks of Accelerate Diagnostics Inc. (NASDAQ:AXDX) traded higher last session on Wall Street, down -5.13% to $0.51.
AXDX stock price is now -17.27% away from the 50-day moving average and -54.50% away from the 200-day moving average. The market capitalization of the company currently stands at $53.84M.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
With the price target maintained at $5, Craig Hallum recently Downgraded its rating from Buy to Hold for Accelerate Diagnostics Inc. (NASDAQ: AXDX)., while ‘Craig Hallum’ rates the stock as ‘Buy’.
In other news, Phillips Jack, Chief Executive Officer sold 7,451 shares of the company’s stock on Mar 13. The stock was sold for $3,651 at an average price of $0.49. Upon completion of the transaction, the Chief Executive Officer now directly owns 473,589 shares in the company, valued at $0.24 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 13, Chief Financial Officer REICHLING STEVEN sold 4,708 shares of the business’s stock. A total of $2,307 was realized by selling the stock at an average price of $0.49. This leaves the insider owning 142,370 shares of the company worth $72608.7. Insiders disposed of 183,455 shares of company stock worth roughly $93562.05 over the past 1 year. A total of 0.80% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in AXDX stock. A new stake in Accelerate Diagnostics Inc. shares was purchased by TEJARA CAPITAL LTD during the first quarter worth $134,000. ACADIAN ASSET MANAGEMENT LLC invested $42,000 in shares of AXDX during the first quarter. In the first quarter, CHARTIST INC /CA/ acquired a new stake in Accelerate Diagnostics Inc. valued at approximately $34,000. DESTINY CAPITAL CORP/CO acquired a new stake in AXDX for approximately $20,000. MILL CREEK CAPITAL ADVISORS, LLC purchased a new stake in AXDX valued at around $8,000 in the second quarter. In total, there are 101 active investors with 27.80% ownership of the company’s stock.
Thursday’s opening bell rang with an opening price of $0.5345 for Accelerate Diagnostics Inc. (NASDAQ: AXDX). During the past 12 months, Accelerate Diagnostics Inc. has had a low of $0.45 and a high of $3.74. The fifty day moving average price for AXDX is $0.6194 and a two-hundred day moving average price translates $1.1261 for the stock.
The latest earnings results from Accelerate Diagnostics Inc. (NASDAQ: AXDX) was released for Sep, 2022. According to the Medical Devices Company, earnings per share came in at -$0.18, beating analysts’ expectations of -$0.19 by 0.01. This compares to -$0.15 EPS in the same period last year. The company reported revenue of $2.96 million for the quarter, compared to $3.12 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -5.19 percent. For the current quarter, analysts expect AXDX to generate $2.87M in revenue.
Accelerate Diagnostics Inc.(AXDX) Company Profile
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.
